Revlon Second Annual Run/Walk for Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 4
Volume 8
Issue 4

NEW YORK-Last year, more than 20,000 people took part in the 5-kilometer Revlon Run/Walk for Women in New York City, raising more than $700,000 to fight women’s cancers. This year’s event will take place on Saturday, May 1, following a route that runs from Times Square to Central Park. The event is produced by Rehage Entertainment, Inc. and the New York Road Runners Club in cooperation with the City of New York.

NEW YORK—Last year, more than 20,000 people took part in the 5-kilometer Revlon Run/Walk for Women in New York City, raising more than $700,000 to fight women’s cancers. This year’s event will take place on Saturday, May 1, following a route that runs from Times Square to Central Park. The event is produced by Rehage Entertainment, Inc. and the New York Road Runners Club in cooperation with the City of New York.

The hotline for the event is 212-218-3327, and the website can be found at www.revlonrunwalk.com. (A similar event is being held in Los Angeles.)

The 1999 beneficiaries of the New York Run/Walk include Cancer Care, Inc., Gilda’s Club, Harlem Hospital Cancer Control Center/Patient Navigator Program, the National Breast Cancer Coalition, and the Ovarian Cancer National Alliance. The co-founders of the event are Lilly Tartikoff, widow of Brandon Tartikoff, former chairman of Paramount Pictures, who died of Hodgkin’s disease, and Ronald O. Perelman, chairman of Revlon.

Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content